Zhejiang Shouxiangu Pharm Co (SHG:603896) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Shouxiangu Pharm Co (603896)
Zhejiang Shouxiangu Pharm Co (SHG:603896) has a market capitalization of $507.08 Million (CN¥3.47 Billion) as of May 4, 2026. Listed on the SHG stock exchange, this China-based company holds position #12463 globally and #3874 in its home market, demonstrating a -4.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Shouxiangu Pharm Co's stock price CN¥17.48 by its total outstanding shares 198243911 (198.24 Million). Analyse 603896 cash flow conversion to see how efficiently the company converts income to cash.
Zhejiang Shouxiangu Pharm Co Market Cap History: 2017 to 2026
Zhejiang Shouxiangu Pharm Co's market capitalization history from 2017 to 2026. Data shows growth from $1.21 Billion to $507.08 Million (4.17% CAGR).
Zhejiang Shouxiangu Pharm Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Shouxiangu Pharm Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.89x
Zhejiang Shouxiangu Pharm Co's market cap is 0.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.52x
Zhejiang Shouxiangu Pharm Co's market cap is 3.52 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.21 Billion | $369.96 Million | $88.88 Million | 3.26x | 13.59x |
| 2018 | $562.22 Million | $511.45 Million | $107.65 Million | 1.10x | 5.22x |
| 2019 | $646.10 Million | $546.76 Million | $123.90 Million | 1.18x | 5.21x |
| 2020 | $761.19 Million | $636.05 Million | $151.71 Million | 1.20x | 5.02x |
| 2021 | $1.27 Billion | $767.14 Million | $200.83 Million | 1.65x | 6.31x |
| 2022 | $1.14 Billion | $829.07 Million | $277.78 Million | 1.37x | 4.10x |
| 2023 | $935.26 Million | $784.35 Million | $254.48 Million | 1.19x | 3.68x |
| 2024 | $615.29 Million | $691.68 Million | $174.71 Million | 0.89x | 3.52x |
Competitor Companies of 603896 by Market Capitalization
Companies near Zhejiang Shouxiangu Pharm Co in the global market cap rankings as of May 4, 2026.
Key companies related to Zhejiang Shouxiangu Pharm Co by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Zhejiang Shouxiangu Pharm Co Historical Marketcap From 2017 to 2026
Between 2017 and today, Zhejiang Shouxiangu Pharm Co's market cap moved from $1.21 Billion to $ 507.08 Million, with a yearly change of 4.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥507.08 Million | -9.80% |
| 2025 | CN¥562.20 Million | -8.63% |
| 2024 | CN¥615.29 Million | -34.21% |
| 2023 | CN¥935.26 Million | -17.86% |
| 2022 | CN¥1.14 Billion | -10.15% |
| 2021 | CN¥1.27 Billion | +66.47% |
| 2020 | CN¥761.19 Million | +17.81% |
| 2019 | CN¥646.10 Million | +14.92% |
| 2018 | CN¥562.22 Million | -53.44% |
| 2017 | CN¥1.21 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Zhejiang Shouxiangu Pharm Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $507.08 Million USD |
| MoneyControl | $507.08 Million USD |
| MarketWatch | $507.08 Million USD |
| marketcap.company | $507.08 Million USD |
| Reuters | $507.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products … Read more